{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:04:27Z","timestamp":1782302667655,"version":"3.54.5"},"reference-count":22,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2021,7,16]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Hepatitis B virus (HBV) can reactivate among rheumatology patients initiating tocilizumab (TCZ) or tofacitinib (TOF). HBV screening is recommended by the Centers for Disease Control and Prevention (CDC), the American Association for the Study of Liver Diseases (AASLD), and the Canadian Rheumatology Association, but it is not explicitly recommended by the American College of Rheumatology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cross-sectional study to characterize HBV screening practices for adult rheumatology patients initiating TCZ or TOF before December 31, 2018, in the Greater Boston area. We classified appropriate HBV screening patterns prior to TCZ or TOF (i.e., HBV surface antigen [HBsAg], total core antibody [anti-HBcAb], and surface antibody [HBsAb]) as follows: complete (all 3 tested), partial (any 1 or 2 tests), or none. We determined the frequency of inappropriate HBV testing (HBV e-antigen, anti-HBcAb IgM, or HBV DNA without a positive HBsAg or total anti-HBcAb) and used multivariable regression to assess factors associated with complete HBV screening.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 678 subjects initiating TCZ, 194 (29%) completed appropriate HBV screening, 307 (45%) had partial screening, and 177 (26%) had none. Among 391 subjects initiating TOF, 94 (24%) completed appropriate HBV screening, 195 (50%) had partial screening, and 102 (26%) had none. Inappropriate testing was performed in 22% of subjects. Race was associated with complete HBV screening (White vs non-White: OR 0.74, 95% CI 0.57\u20130.95), whereas prior immunosuppression was not (conventional synthetic disease-modifying antirheumatic drugs [DMARDs]: OR 1.05, 95% CI 0.72\u20131.55; biologic DMARDs: OR 0.73, 95% CI 0.48\u20131.12).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients initiating TCZ or TOF are infrequently screened for HBV despite recommendations from the AASLD and CDC.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.210257","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T12:25:14Z","timestamp":1627820714000},"page":"104-109","source":"Crossref","is-referenced-by-count":12,"title":["Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-6154","authenticated-orcid":false,"given":"Amir M.","family":"Mohareb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-0346","authenticated-orcid":false,"given":"Naomi J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-7038","authenticated-orcid":false,"given":"Zachary S.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-106X","authenticated-orcid":false,"given":"Emily P.","family":"Hyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2021,8,1]]},"reference":[{"key":"2024092708501820000_49.1.104.1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-10-201205150-00013"},{"key":"2024092708501820000_49.1.104.2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1121"},{"key":"2024092708501820000_49.1.104.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-7-200804010-00008"},{"key":"2024092708501820000_49.1.104.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.038"},{"key":"2024092708501820000_49.1.104.5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.semarthrit.2020.03.003","article-title":"RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs","volume":"50","author":"Schmajuk","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2024092708501820000_49.1.104.6","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2024092708501820000_49.1.104.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"2024092708501820000_49.1.104.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110207"},{"key":"2024092708501820000_49.1.104.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22783"},{"key":"2024092708501820000_49.1.104.10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/acr.20209","article-title":"Rheumatologists\u2019 awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy","volume":"62","author":"Stine","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2024092708501820000_49.1.104.11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/acr.23241","article-title":"Practice pattern of hepatitis B testing in rheumatoid arthritis patients: a cross-national comparison between the US and Taiwan","volume":"70","author":"Lin","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2024092708501820000_49.1.104.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02332.x"},{"key":"2024092708501820000_49.1.104.13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2024092708501820000_49.1.104.14","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1705785"},{"key":"2024092708501820000_49.1.104.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1126"},{"key":"2024092708501820000_49.1.104.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211322"},{"key":"2024092708501820000_49.1.104.17","doi-asserted-by":"crossref","first-page":"e0219347","DOI":"10.1371\/journal.pone.0219347","article-title":"Hepatitis B testing practices at a tertiary care centre and their associated costs: a retrospective analysis","volume":"14","author":"Lawandi","year":"2019","journal-title":"PLoS One"},{"key":"2024092708501820000_49.1.104.18","doi-asserted-by":"crossref","first-page":"u211376.w4582","DOI":"10.1136\/bmjquality.u211376.w4582","article-title":"Reducing inappropriate ESR testing with computerized clinical decision support","volume":"5","author":"Gottheil","year":"2016","journal-title":"BMJ Qual Improv Rep"},{"key":"2024092708501820000_49.1.104.19","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000450"},{"key":"2024092708501820000_49.1.104.20","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s10620-016-4118-1","article-title":"Gastroenterologists have suboptimal hepatitis B virus screening rates in patients receiving immunosuppressive therapy","volume":"61","author":"Paul","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2024092708501820000_49.1.104.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120749"},{"key":"2024092708501820000_49.1.104.22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28026"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:50:45Z","timestamp":1727452245000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,1]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.3899\/jrheum.210257"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210257","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}